`
`
`Filed on behalf of:
`Mylan Pharmaceuticals Inc.
`Joseph M. Reisman
`Jay R. Deshmukh
`
`KNOBBE, MARTENS, OLSON & BEAR, LLP
`2040 Main Street, 14th Floor
`Irvine, CA 92614
`Fax: (949) 760-9502
`Ph.: (949) 760-0404
`E-mail: BoxMylan2@knobbe.com
`
`By:
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`__________________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`__________________________________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner
`
`v.
`
`NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
`Patent Owners
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2015-00268
`Patent 6,335,031
`
`
`
`
`
`
`
`
`MYLAN EXHIBIT LIST
`
`
`
`
`
`
`
`
`IPR2015-00268
`Mylan v. Novartis
`
`
`Pursuant to 37 C.F.R. § 42.63(e), Petitioner Mylan Pharmaceuticals Inc.
`
`(“Mylan”) hereby provides a current list of its exhibits filed thus far in this case.
`
`Exhibit No.
`
`MYLAN EXHIBIT LIST
`
`
`Description
`
`Ex. 1001
`
`U.S. Patent No. 6,335,031, issued January 1, 2002
`
`Ex. 1002
`
`Ex. 1003
`
`Ex. 1004
`
`Ex. 1005
`
`Ex. 1006
`
`Ex. 1007
`
`UK Patent Application GB 2,203,040 A, to Enz, published
`October 12, 1988 (“Enz”)
`
`Handbook of Pharmaceutical Excipients, A. Wade and P. J.
`Weller (eds.) 1994, 2nd Edition, The Pharmaceutical Press
`London (the “Handbook”)
`
`Japanese Patent Application Publication No. JP 59-184121
`to Sasaki et al., published October 19, 1984
`
`Certified English Translation of Japanese Patent
`Application Publication No. JP 59-184121 to Sasaki et al.
`(“Sasaki”)
`
`PCT Publication No. WO 95/024172 to Ebert et al,
`published September 14, 1995 (“Ebert”)
`
`Carey & Sundberg, ADVANCED ORGANIC CHEMISTRY,
`2nd ed. Part A: Structure and Mechanism, Plenum Press, New
`York, 1984, pp. 652
`
`Ex. 1008
`
`U.S. Patent 4,948,807 (“Rosin”)
`
`Ex. 1009
`
`Elmalem et al. 1991, Neuropharmacology 30: 1059-1064
`(“Elmalem”)
`
`Ex. 1010
`
`Declaration of Agis Kydonieus, Ph.D.
`
`Ex. 1011
`
`Declaration of Christian Schöneich, Ph.D.
`
`1
`
`
`
`IPR2015-00268
`Mylan v. Novartis
`
`
`Exhibit No.
`
`Ex. 1012
`
`Ex. 1013
`
`Ex. 1014
`
`Ex. 1015
`
`Ex. 1016
`
`Ex. 1017
`
`Ex. 1018
`
`Ex. 1019
`
`Ex. 1020
`
`Ex. 1021
`
`Description
`
`“Safety/Tolerability Trial of SDZ ENA 713 in Patients with
`Probable Alzheimer’s Disease,” John J. Sramek et al., Life
`Sciences, Vol. 58, No. 15, pp. 1201-1207 (1996) (“Sramek”)
`
`“New acetylcholinesterase inhibitor shows promise in largest
`Alzheimer’s trial to date,” Formulary, Vol. 32, Dec. 1997
`(“Formulary Article”)
`
`ICH Topic Q 1 A, Stability Testing Guidelines: Stability Testing
`of New Drug Substances and Products (CPMP/ICH/380/95)
`
`Connors, Amidon, & Stella, Oxidation and Photolysis in Chemical
`Stability of Pharmaceuticals – A Handbook for Pharmacists (2nd
`Edition), John Wiley & Sons, NY (1986), pp. 82-114
`
`Howard C. Ansel, Introduction to Pharmaceutical Dosage Forms,
`4th Edition, Lea & Febiger, Philadelphia (1985), pp. 83-116
`
`Ho-Leung Fung, Chapter 7 – Chemical Kinetics and Drug Stability
`in MODERN PHARMACEUTICS (G.S. Banker and C.T. Rhodes,
`eds.), Marcel Dekker, NY (1978), pp. 227-62
`
`Miguel-Hidalgo, J., 2000, Current Opinion in CPNS Investigations
`Drugs, 2000 2(4):438-453
`
`Boccardi G. et al. Photochemical Iron(III)-Mediated Autoxidation
`of Dextromethorphan. Chemical & Pharmaceutical Bulletin. Vol.
`37, 308–310 (1989)
`
`Bateman, L., Olefin Oxidation, Quarterly Review (1954) Vol. 8,
`pp. 147–167
`
`Linnell, R.H., The Oxidation of Nicotine. I. Kinetics of the Liquid
`Phase Reaction Near Room Temperature. Tobacco Science, Vol.
`4, pp. 89–90 (1960)
`
`2
`
`
`
`IPR2015-00268
`
`Mylan V. Novartis
`
`
`
`
`
`
`
`Ex. 1025
`
`EXHIBIT NUIVIBER INTENTIONALLY NOT USED
`
`EX. 1026
`
`
`
`
`Declaration ofWilliam. R. Zimmerman in Support of Motion to
`Appear Pro Hac Vice on Behalf of petitioner Mylan
`Pharmaceuticals Inc.
`
`Respectfully submitted,
`
`KNOBBE, MARTENS, OLSON & BEAR, LLP
`
`
`
`
`
`
`
`Dated: December 10 2014
`
`By:
`
`
`
`oseph M. Reisman
`Reg. No. 43,878
`Customer No. 20,995
`
`
`
`Attorneys for Petitioner
`MYLAN PHARMACEUTICALS INC.
`
`(949) 760-0404
`
`
`
`IPR2015—00268
`
`Mylan V. Novartis
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that a true and correct copy of the foregoing MYLAN
`
`EXHIBIT LIST is being served on December 10, 2014, Via email pursuant to 37
`CPR. § 42.6(e) per agreement of the parties, to counsel for Novartis AG and LTS
`
`Lohmann Therapie—Systeme AG at the address below:
`
`ExelonPatchIPRQchhscom
`
`Raymond R. Mandra
`Fitzpatrick, Cella, Harper & Scinto
`1290 Avenue of the Americas
`
`New York, NY 10104
`
`
`Dated: December 10 2014
`
`2&2
`
`
`seph M.,Reisman, Reg. No. 43,878
`Attorney for Petitioner
`Mylan Pharmaceuticals Inc.
`
`19436865
`
`